Drugs / SYNB1891
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04167137 | Dec 2019 → Dec 2021 | lymphoma, metastatic malignant neoplasm | Synlogic | Terminated | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SYNB1891 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04167137 ↗ |
| Action | Activate | “leading to STimulator of INterferon Genes (STING) activation” PMID 37227176 ↗ Jul 2023 |
| Modality | Other / unclassified | “SYNB1891 is a live, modified strain of the probiotic Escherichia coli Nissle 1917 (EcN) engineered to produce cyclic dinucleotides under hypoxia” PMID 37227176 ↗ Jul 2023 |
| Route | Other | “SYNB1891 was administered as an IT injection” NCT04167137 ↗ |